Publications by authors named "Michelle Xia"

Claim this Profile
I
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Zhiwei Chen, Fang Yang, Zhou Jiang, Longhua Sun, Lin Wu, Zhengxiang Han, Xiangjiao Meng, Runxiang Yang, Xiaohong Ai, Xingxiang Pu, Michelle Xia

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of monoclonal antibody AK111 in the treatment of active ankylosing spondylitis: a randomised, double-blind, placebo-controlled, multicentre phase II clinical study.
Hua Ye, Shengyun Liu, Yongjun Mei, Jieruo Gu, Min Yang, Michelle Xia

Clin Exp Rheumatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Lin Shen, Yanqiao Zhang, Ziyu Li, Xiaotian Zhang, Xiangyu Gao, Wenxiang Dai, Xiaoqin Li, Zhixiang Zhuang, Michelle Xia, Xiangji Ying

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Lin Shen, Yanqiao Zhang, Ziyu Li, Xiaotian Zhang, Xiangyu Gao, Wenxiang Dai, Xiaoqin Li, Zhixiang Zhuang, Michelle Xia, Xiangji Ying

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial.
Juan Zhang, Yu-Xin Fan, Yu Huang, Runfang Guan, Ruixia Li, Shuxian Long, Xia Gong, Michelle Xia

Drug Des Devel Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects.
Tingting Zhong, Lingzhi Zhang, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Michelle Xia

iScience· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu, Baogang Liu, Zhengxiang Han, Xiaohong Ai, Xiaodong Mei, Michelle Xia

Lancet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Xiaohua Wu, Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Xiaohong Wang, Xianling Liu, Yunxia Li, Xiaojian Yan, Bairong Xia, Michelle Xia

Lancet· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab.
Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Michelle Xia

Pharmacol Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

JAMA· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
Xiangyu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Qingxia Fan, Xiaoyan Lin, Hongxia Yang, Michelle Xia

Nat Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Qiu-Yan Chen, Shan-Shan Guo, Ying Luo, Song Qu, De-Hua Wu, Xiao-Zhong Chen, Michelle Xia

Oral Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Sophia Frentzas, Hui K Gan, Rasha Cosman, Jermaine Coward, Ben Tran, Dennis Xia, Michelle Xia

Cell Rep Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Yuxian Bai, Michelle Xia

Front Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang, Michelle Xia

Dermatol Ther (Heidelb)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Xiangyu Gao, Nong Xu, Ziyu Li, Lin Shen, Ke Ji, Yunxia Li, Qingxia Fan, Xiaoyan Lin, Xiaofan Li, Xiaohong Liu, Hongxia Yang, Michelle Xia, Xiaohua Wu

Lancet Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Yuanyuan Zhao, Gang Chen, Jianhua Chen, Li Zhuang, Yingying Du, Michelle Xia

EClinicalMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia

MAbs· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bayesian approach to simultaneous adjustment of misclassification and missingness in categorical covariates.
Michelle Xia, Rexford M Akakpo

Stat Methods Med Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis.
Qian Li, Ju Qiao, Hongzhong Jin, Benchao Chen, Zhimei He, Xiang Ni, Michelle Xia

Front Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Zhaoliang Huang, Xinghua Pang, Tingting Zhong, Tailong Qu, Na Chen, Dennis Xia, Michelle Xia

Front Immunol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rehabilitation technology services and employment outcomes among consumers using division of rehabilitation services.
Matthew Evan Sprong, Bryan Dallas, Erina Paul, Michelle Xia

Disabil Rehabil Assist Technol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
Iván González, Bella Goyal, Michelle D Xia, Reetesh K Pai, Changqing Ma

Hum Pathol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian inference for unidirectional misclassification of a binary response trait.
Michelle Xia, Paul Gustafson

Stat Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A general framework for constraint approaches to adjusted risk differences.
Yuanyuan Tang, Michelle Xia, Liangrui Sun, John A Spertus, Philip G Jones

Biom J· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis